首页> 外国专利> HUMAN NOTCH1 BASED FUSION PROTEINS AS DECOY INHIBITORS OF JAGGED-NOTCH SIGNALING AND DLL-NOTCH SIGNALING

HUMAN NOTCH1 BASED FUSION PROTEINS AS DECOY INHIBITORS OF JAGGED-NOTCH SIGNALING AND DLL-NOTCH SIGNALING

机译:基于人Notch1的融合蛋白作为杂化缺口信号和DLL缺口信号的诱饵抑制剂

摘要

This invention provides a fusion protein, the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of amino acids in: (a) an extracellular domain of a human Notch1 receptor protein, followed by (b) an Fc portion of an antibody, wherein the extracellular domain of the human Notch1 receptor protein (i) commences with the amino acid present at the N-terminus of EGF-like repeat 10 and (ii) extends to and includes the C-terminal amino acid of EGF-like repeat 18 or 20. Also provided is a composition comprising the any of the fusion proteins of this invention and a pharmaceutically acceptable carrier, a method of treating a subject suffering from age-related macular degeneration (AMD), diabetic retinopathy, or cancer which comprises administering to the subject any of the compositions of this invention in an amount effective to treat the subject's cancer.
机译:本发明提供了一种融合蛋白,其序列从该融合蛋白的N端开始,与以下氨基酸序列相同:(a)人Notch1受体蛋白的胞外域,然后是(b) )抗体的Fc部分,其中人Notch1受体蛋白的胞外域(i)以存在于EGF样重复序列10的N端的氨基酸开始,并且(ii)延伸至C端并包括C端EGF-样重复序列18或20的氨基酸。还提供了包含本发明的任何融合蛋白和药学上可接受的载体的组合物,治疗患有年龄相关性黄斑变性(AMD)的糖尿病的对象的方法视网膜病或癌症,其包括以有效治疗受试者癌症的量向受试者给药本发明的任何组合物。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号